A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs

Por Kallen, Karl-Josef, Theß, Andreas
Publicado em 2014

mRNA as novel technology for passive immunotherapy

Por Schlake, Thomas, Thess, Andreas, Thran, Moritz, Jordan, Ingo
Publicado no Cell Mol Life Sci (2018)

Developing mRNA-vaccine technologies

Por Schlake, Thomas, Thess, Andreas, Fotin-Mleczek, Mariola, Kallen, Karl-Josef
Publicado em 2012

Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals

Por Thess, Andreas, Grund, Stefanie, Mui, Barbara L, Hope, Michael J, Baumhof, Patrick, Fotin-Mleczek, Mariola, Schlake, Thomas
Publicado no Mol Ther (2015)

Production and characterisation of monoclonal antibodies against RAI3 and its expression in human breast cancer

Por Jörißen, Hannah, Bektas, Nuran, Dahl, Edgar, Hartmann, Arndt, ten Haaf, Anette, Di Fiore, Stefano, Kiefer, Hans, Thess, Andreas, Barth, Stefan, Klockenbring, Torsten
Publicado em 2009

A novel, disruptive vaccination technology: Self-adjuvanted RNActive(®) vaccines

Por Kallen, Karl-Josef, Heidenreich, Regina, Schnee, Margit, Petsch, Benjamin, Schlake, Thomas, Thess, Andreas, Baumhof, Patrick, Scheel, Birgit, Koch, Sven D, Fotin-Mleczek, Mariola
Publicado em 2013

mRNA mediates passive vaccination against infectious agents, toxins, and tumors

Por Thran, Moritz, Mukherjee, Jean, Pönisch, Marion, Fiedler, Katja, Thess, Andreas, Mui, Barbara L, Hope, Michael J, Tam, Ying K, Horscroft, Nigel, Heidenreich, Regina, Fotin‐Mleczek, Mariola, Shoemaker, Charles B, Schlake, Thomas
Publicado no EMBO Mol Med (2017)